DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for gastrointestinal disease — screening already-approved drugs against its 40-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGastrointestinal disease maps to a 40-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gastrointestinal disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphodiesterase 4D (PDE4D) — PDE4D is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet difluoromethoxydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5WH6 · 1.6 Å · ligand 1-[4-(difluoromethoxy)-3-{[(3S)-oxolan-3-yl]oxy}phenyl]-3-methylbutan-1-one (AKJ). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAMA · 1981 · 30 citations
Genetics and Heterogeneity of Common Gastrointestinal Disorders
AbstractThis book presents the edited manuscripts of presentations made during an international workshop held in March 1980. Investigators attempted to assess current knowledge of genetics in gastrointestinal disease with the fostering of future research as a major goal. The presentations were of several kinds. One set related to genetics per se, with titles such as "Approaches to the Genetics of Common Diseases," "The Analysis of Pedigree Information," and "Twins and Twin Methods as Genetic Epidemiologic Tools." Another presented clinical information about various gastrointestinal diseases. Thus, there were brief discussions of peptic ulcer, gallstones, and inflammatory bowel disease. The sections on genetics presumably were designed for nongeneticists in the audience and the clinical discussions for nonclinicians. Finally, some presentations reviewed data concerning genetic associations with these disorders. The major problem in reviewing the book is to try to gauge its audience. For those not knowledgeable in genetics, it is not a
Canadian Journal of Gastroenterology · 2003 · 0 citations · open access
Meeting Report: Research Topics in Gastrointestinal Disease III
AbstractC urrent advances in therapeutics of gastrointestinal (GI) diseases are a direct result of the rapid developments in fundamental research of cellular and molecular biology and its specific application to defining the normal physiology of the GI tract and the pathogenetic mechanisms underlying disease processes. The Canadian GI research community has contributed greatly to these efforts and continues to be a world leader in all disciplines relevant to GI disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
